The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates.

Authors

AeRang Kim, Children's National Medical Center, Washington, DC
Cindy McCully, National Cancer Institute, Bethesda, MD
Raphael Cruz, National Cancer Institute, Bethesda, MD
Diane E. Cole, National Cancer Institute, Bethesda, MD
Elizabeth Fox, Children's Hospital Philadelphia
Frank M. Balis, Children's Hospital Philadelphia
Brigitte C. Widemann, National Cancer Institute, Bethesda, MD

Document Type

Journal Article

Publication Date

4-2012

Journal

Investigational New Drugs

Volume

Volume 30, Issue 2

Inclusive Pages

524-528

Keywords

Antineoplastic Agents--administration & dosage; Antineoplastic Agents--pharmacokinetics; Benzenesulfonates--administration & dosage; Benzenesulfonates--pharmacokinetics; Protein Kinase Inhibitors--administration & dosage; Protein Kinase Inhibitors--pharmacokinetics; Pyridines--administration & dosage; Pyridines--pharmacokinetics

APA Citation

Kim, A., McCully, C., Cruz, R., Cole, D. E., Fox, E., Balis, F. M., & Widemann, B. C. (2012). The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates. Investigational New Drugs, 30(2), 524-528.

Peer Reviewed

1